How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations.


Journal

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
ISSN: 1809-452X
Titre abrégé: Braz J Psychiatry
Pays: Brazil
ID NLM: 100895975

Informations de publication

Date de publication:
Historique:
received: 01 03 2020
accepted: 02 04 2020
pubmed: 4 6 2020
medline: 27 4 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

Adherence to antidepressants is crucial for optimal treatment outcomes when treating depressive disorders. However, poor adherence is common among patients prescribed antidepressants. This targeted review summarizes the main factors associated with poor adherence, interventions that promote antidepressant adherence, pharmacological aspects related to antidepressant adherence, and formulates 10 clinical recommendations to optimize antidepressant adherence. Patient-related factors associated with antidepressant non-adherence include younger age, psychiatric and medical comorbidities, cognitive impairment, and substance use disorders. Prescriber behavior-related factors include neglecting medical and family histories, selecting poorly tolerated antidepressants, or complex antidepressant regimens. Multi-disciplinary interventions targeting both patient and prescriber, aimed at improving antidepressant adherence, include psychoeducation and providing the patient with clear behavioral interventions to prevent/minimize poor adherence. Regarding antidepressant choice, agents with individually tailored tolerability profile should be chosen. Ten clinical recommendations include four points focusing on the patient (therapeutic alliance, adequate history taking, measurement of depressive symptoms, and adverse effects improved access to clinical care), three focusing on prescribing practice (psychoeducation, individually tailored antidepressant choice, simplified regimen), two focusing on mental health services (improved access to mental health care, incentivized adherence promotion and monitoring), and one relating to adherence measurement (adherence measurement with scales and/or therapeutic drug monitoring).

Identifiants

pubmed: 32491040
pii: S1516-44462020005015208
doi: 10.1590/1516-4446-2020-0935
pmc: PMC8023158
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-202

Auteurs

Marco Solmi (M)

Dipartimento di Neuroscienze, Università di Padova, Padova, Italy.
Azienda Ospedale Università di Padova, Padova, Italy.

Alessandro Miola (A)

Dipartimento di Neuroscienze, Università di Padova, Padova, Italy.

Giovanni Croatto (G)

Dipartimento di Neuroscienze, Università di Padova, Padova, Italy.

Giorgio Pigato (G)

Azienda Ospedale Università di Padova, Padova, Italy.

Angela Favaro (A)

Dipartimento di Neuroscienze, Università di Padova, Padova, Italy.
Azienda Ospedale Università di Padova, Padova, Italy.

Michele Fornaro (M)

Dipartimento di psichiatria, Università Federico II, Napoli, Italy.
Polyedra, Teramo, Italy.

Michael Berk (M)

Institute for Mental and Physical Health and Clinical Translation (IMPACT Strategic Research Centre), School of Medicine, Barwon Health, Deakin University, Geelong, Victoria, Australia.
Department of Psychiatry, Orygen - The Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia.

Lee Smith (L)

Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.

Joao Quevedo (J)

Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Neurociências, Unidade de Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brazil.
Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Department of Psychiatry and Behavioral Sciences, Center of Excellence on Mood Disorders, McGovern Medical School, UTHealth, Houston, TX, USA.
Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.

Michael Maes (M)

IMPACT Strategic Research Centre, Barwon Health, School of Medicine, Deakin University, Geelong, Victoria, Australia.

Christoph U Correll (CU)

Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.
Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.

André F Carvalho (AF)

IMPACT Strategic Research Centre, Barwon Health, School of Medicine, Deakin University, Geelong, Victoria, Australia.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Centre for Addiction and Mental Health, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH